The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | How treatment regimens in myeloma have changed: discussions at COMy 2022
In this video, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the division of multiple myeloma treatment algorithms into two categories: the transplant-eligible patients, and the transplant-ineligible patients. Dr Mohty highlights the various ways in which treatment regimens have evolved over the last few years, including changes made to induction regimens, consolidation, and maintenance therapy. These topics will all be addressed by specialists at COMy 2022.
